Top Markets
Coin of the day
Yumanity Therapeutics, Inc. Yumanity Therapeutics, Inc.

Yumanity Therapeutics, Inc.

YMTX
Rankning i aktier #28846
Yumanity Therapeutics Inc. operates as a clinical-stage biopharmaceutical... Yumanity Therapeutics Inc. operates as a clinical-stage biopharmaceutical company. Its primary focus lies in the investigation and development of therapeutic solutions for neurodegenerative conditions, particularly those driven by protein misfolding. The firm aims to discover disease-modifying treatments for a range of neurodegenerative disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis (ALS), and frontotemporal lobar degeneration. Central to its pipeline is YTX-7739, an innovative small molecule presently in Phase I clinical trials for Parkinson's disease and associated α-synuclein disorders. Additionally, YTX-9184 is undergoing preclinical studies with the goal of treating diverse neurological conditions. The company maintains a license and research collaboration agreement with Merck Sharp & Dohme Corp. Founded in 2014, Yumanity Therapeutics Inc. is headquartered in Boston, Massachusetts.
Aktiekurs
$1.89
Senast synkroniserad: 2022-12-16
Marknadsvärde
$24.38M
Förändring (1 dag)
8.62%
Förändring (1 år)
0.00%
Land
US
Handel Yumanity Therapeutics, Inc. (YMTX)

Kategori

Utdelningsavkastning för Yumanity Therapeutics, Inc. (YMTX)
Utdelningsavkastningen (TTM) för Yumanity Therapeutics, Inc. (aktiesymbol: YMTX) per 2026 är: 0
Genomsnittlig utdelningsavkastning de senaste 5 åren: 0.00%
Historik för utdelningsavkastning för Yumanity Therapeutics, Inc. (YMTX) från 2026 till 2026
Utdelningsavkastning i slutet av varje år (TTM)
År Utdelningsavkastning Ändra
Inte tillräckligt med data för de angivna datumen.
Utdelningsavkastning (TTM) för liknande företag eller konkurrenter
Företag Utdelningsavkastning Land
0.00%
US
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH